These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10647204)

  • 41. [Ergometric evaluation of slow-release isosorbide-5-mononitrate in exertional angina with stable threshold].
    Fazzini PF; Pucci P
    Cardiologia; 1987 Nov; 32(11):1297-302. PubMed ID: 3447703
    [No Abstract]   [Full Text] [Related]  

  • 42. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
    Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
    Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Withdrawal of intravenous glyceryl trinitrate: absence of rebound phenomena with transition to oral isosorbide dinitrate.
    Kelly EA; Ahmed RM; Horowitz JD
    Clin Exp Pharmacol Physiol; 2005 Apr; 32(4):269-72. PubMed ID: 15810990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Linsidomine, direct donor of EDRF/NO: a new treatment for unstable angina].
    Delonca J; Giraud T; Lennuyeux E; Charansonney O
    Arch Mal Coeur Vaiss; 1996 Oct; 89 Spec No 5():19-25. PubMed ID: 8952816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hemodynamic effect, effect duration and pharmacokinetics of 80 mg of isosorbide-5-mononitrate in acute myocardial infarct].
    Reifart N; Bussmann WD; Schirmer M; Kaltenbach M
    Med Welt; 1981 Apr; 32(14A):540-2. PubMed ID: 7242317
    [No Abstract]   [Full Text] [Related]  

  • 47. Isosorbide-5-mononitrate in angina pectoris.
    Poss M; Racicot D; Kiser WR
    Ann Intern Med; 1994 Oct; 121(7):547. PubMed ID: 8093205
    [No Abstract]   [Full Text] [Related]  

  • 48. [Efficacy and duration of action of isosorbide-5-mononitrate in the treatment of stable angina of effort. Comparison with sustained-release isosorbide dinitrate].
    Lagioia R; Scrutinio D; Mangini SG; De Toma L; Accettura D; De Nicolò M; Saliani P; Preziusi N; Antuofermo F; Rizzon P
    G Ital Cardiol; 1985 Mar; 15(3):299-306. PubMed ID: 4018470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nitrate tolerance.
    Kendall MJ
    Am Heart J; 1995 Jun; 129(6):1223-4. PubMed ID: 7754960
    [No Abstract]   [Full Text] [Related]  

  • 50. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Use of nitro preparations in the acute period of myocardial infarct].
    Gvatua NA; Kravtsov VL; Shumakov VA; Ivanova LK; Shkliar LV
    Ter Arkh; 1979; 51(11):17-21. PubMed ID: 118540
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
    Neuhaus R; Johnen R; Vydra L; Solbach C
    Pharmatherapeutica; 1986; 4(8):486-95. PubMed ID: 3086899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Drug therapy in angina pectoris].
    Follath F
    Praxis (Bern 1994); 1995 Oct; 84(42):1186-9. PubMed ID: 7481332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The use of oral and intravenous isosorbide mononitrate (5-MNi) in the acute phase of myocardial infarction].
    Rezende M
    Rev Port Cardiol; 1993 Mar; 12 Suppl 1():I35-8. PubMed ID: 8499118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Endothelial dysfunction in patients with chronic heart failure, and possibilities of its correction with isosorbide-5-mononitrates].
    Ol'binskaia LI; Sizova ZhM; Kolbaia NG
    Klin Med (Mosk); 2007; 85(1):27-31. PubMed ID: 17419351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Continuous long-term dosing with oral slow-release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction.
    Kanamasa K; Hayashi T; Takenaka T; Kimura A; Ikeda A; Ishikawa K;
    Clin Cardiol; 2001 Sep; 24(9):608-14. PubMed ID: 11558843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Influence of nitrates on red blood cell deformability and clinical parameters in patients with silent ischemia].
    Dłuzniewski M; Lada W; Mamcarz A; Raczkowska A; Król J; Podogrodzka B; Jurgiel R; Swiatowiec A; Sitkiewicz W; Pawińska M; Janas J; Kuch J
    Pol Merkur Lekarski; 1997 Jan; 2(9):179-83. PubMed ID: 10907022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy of mononitrate retard therapy in patients with advanced congestive heart failure].
    Chmielewski M; Mamcarz A; Dłuzniewski M; Braksator W; Król J; Krysztofiak H; Kuch M; Beranek G
    Pol Merkur Lekarski; 1997 Sep; 3(15):101-4. PubMed ID: 9461702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isosorbide 5-mononitrate in the treatment of left ventricular failure following acute myocardial infarction.
    Murray RG; Gammage MD
    Cardiology; 1987; 74 Suppl 1():58-9. PubMed ID: 3607805
    [No Abstract]   [Full Text] [Related]  

  • 60. Monitoring medical management of coronary artery disease: patient selection, optimal management, and potential problems for diagnosis.
    Cerqueira MD
    J Nucl Cardiol; 2000; 7(4):392-4. PubMed ID: 10958283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.